AI-Enhanced Analysis of Breast Density and Background Parenchymal Enhancement (BPE)

February 15, 2025 updated by: Graziella di Grezia, Link Campus University
This study expands upon previous research investigating the correlation between breast density, Background Parenchymal Enhancement (BPE), and age in contrast-enhanced mammography (CEM). By integrating Artificial Intelligence (AI) methodologies, including Artificial Neural Networks (ANNs) and deep learning models, the study aims to optimize the accuracy of predictions and validate prior findings obtained through multiple linear regression.

Study Overview

Status

Enrolling by invitation

Study Type

Observational

Enrollment (Estimated)

213

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Naples, Italy, 80138
        • University of Campania Luigi Vanvitelli

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Women aged 18 years and older who underwent CEM for diagnostic or surveillance purposes.

Patients with recorded BPE levels and BI-RADS breast density classification.

Relational database containing structured data for correlation matrix analysis and AI model training.

Description

Patients who underwent CEM, mammography, and ultrasound between May 2022 and June 2023.

Availability of BPE assessment, BI-RADS density classification, and age data.

Complete dataset available for statistical and AI-based analysis.

Exclusion Criteria:

Patients with prior breast cancer treatment that could alter BPE.

Incomplete imaging or missing classification data.

Contraindications to contrast-enhanced imaging.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
patiens underwent CEM

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between breast density, BPE, and age using AI-driven analysis.
Time Frame: Data analysis within 12 months of study completion.
Evaluating whether AI models, including neural networks, can enhance prediction accuracy for BPE assessment compared to conventional multiple linear regression.
Data analysis within 12 months of study completion.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
AI-based optimization of breast density and BPE classification
Time Frame: Within 12 months of study completion
Evaluating the performance of neural networks in predicting BPE levels across different breast density categories.
Within 12 months of study completion
Comparative performance of multiple linear regression vs. AI models.
Time Frame: Within 12 months of study completion.
Assessing the accuracy of traditional statistical methods versus ANN-based predictions in explaining variance in BPE values.
Within 12 months of study completion.
Mean Squared Error (MSE) and explained variance in predictive models
Time Frame: Within 12 months of study completion
Analyzing the error rates and variance explained by different AI models compared to multiple linear regression.
Within 12 months of study completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Actual)

June 30, 2023

Study Completion (Estimated)

February 1, 2025

Study Registration Dates

First Submitted

February 15, 2025

First Submitted That Met QC Criteria

February 15, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 15, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • T_6_2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Artificial Intelligence (AI)

Subscribe